Chlamydial infections are the most prevalent bacterial sexually transmitted infections recognised throughout the world. According to the WHO, 50-70 million chlamydial infections are detected annually worldwide.' In most developed countries, sexually transmitted chlamydial infections are still strikingly common particularly among adolescents, and 10-20 times more common than gonococcal infections.' In our recent study, the prevalence of Chlamydia trachomatis infection was 5.6% among asymptomatic women attending a family planning clinic and a student health clinic.2 Chlamydial infections cause major medical, social, and economic problems. Sequelae of C trachomatis infection are extremely costly to the healthcare system, and include pelvic inflammatory disease (PID), ectopic pregnancy, tubal factor infertility (TFI), epididymitis, proctitis, and arthritis. Chlamydial infections, like STDs in general, are primarily a woman's healthcare issue since the manifestations and consequences in women are more damaging to the reproductive tract than in men. Expensive medical high technology, such as in vitro fertilisation (IVF), has largely emerged because of reproductive tract damage caused by sexually transmitted chlamydial infections. There is a strong link between past chlamydial infection and TFI or ectopic pregnancy. Emerging evidence suggests that C trachomatis infection is a significant risk factor for other adverse pregnancy outcomes-that is, preterm delivery and spontaneous abortion.3 Recent studies also suggest that C trachomatis infection is an independent risk factor for the development of cervical neoplasia.' 6 Since chlamydial infections are usually asymptomatic, the key to the prevention of chlamydial infections and their sequelae is screening using a high performance diagnostic test Cost analyses are becoming more common among trials which compare therapeutic or procedural healthcare interventions.8 12 The most widely known form of economic evaluation is cost-benefit analysis.'3 It is restricted to those forms of evaluation that are used to place a monetary value on benefits and outcomes. This makes cost-benefit analysis the most comprehensive and theoretically sound form of economic evaluation. On the other hand, in cost effectiveness analysis the outcomes are not measured in monetary units, but in clinical units such as cases of PID or TFI.'4 Recent studies have addressed the cost effectiveness of identifying and treating C trachomatis infections in asymptomatic women.'5 16 Genc and Mardh"5 showed that when the prevalence of chlamydial infection exceeded 6%, screening of women with DNA amplification assay of endocervical swabs (and treatment of positive women with a single oral dose of azithromycin) was the most cost effective intervention strategy. If the prevalence was even higher, screening with enzyme immunoassay of cervical specimens also generated savings and improved the cure rates compared with a "no screening" situation. Diagnosis of C trachomatis by tissue cell culture of cervical swabs was cost effective only when the prevalence of infection was greater than 14%. Most of the savings generated by the screening strategy were attributable to prevention of complications and sequelae of chlamydial infection in women. However, the study anticipated that only women who have clinical symptoms of PID are at risk for infertility, ectopic pregnancy, or chronic pelvic pain. Hence, subclinical or silent upper genital tract infections caused by C trachomatis were not considered. We recently developed a computer based decision tree model in order to conduct a more thorough cost-benefit analysis of screening versus no screening situation, based on testing of first void urine specimens with PCR among women.'7 The decision tree
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There is clear evidence that systematic screening of asymptomatic populations decreases the incidence of C trachomatis infections. This has been documented both in nationwide screening programmes22 and in screening programmes performed in other defined populations in which the screening activity has remained stable.23 Furthermore, recent randomised clinical trial have shown that intervention with selective screening of chlamydial infections effectively reduces the incidence of PID.7 It still remains to be seen whether such intervention will also have a significant effect on the rate of long term sequelae of chlamydial infections.
Since C trachomatis is the major cause of female genital tract infections and infertility and adverse pregnancy outcome, prevention and control of these infections and their sequelae will have a major impact on the reproductive health of women. Further socioeconomic studies linking the cost of secondary prevention of C trachomatis infections and the cost of infertility or adverse pregnancy outcome are warranted.
